167 related articles for article (PubMed ID: 27161435)
21. Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas.
Nakamura T; Tateishi K; Niwa T; Matsushita Y; Tamura K; Kinoshita M; Tanaka K; Fukushima S; Takami H; Arita H; Kubo A; Shuto T; Ohno M; Miyakita Y; Kocialkowski S; Sasayama T; Hashimoto N; Maehara T; Shibui S; Ushijima T; Kawahara N; Narita Y; Ichimura K
Neuropathol Appl Neurobiol; 2016 Apr; 42(3):279-90. PubMed ID: 26111727
[TBL] [Abstract][Full Text] [Related]
22. Non-invasive detection of somatic mutations using next-generation sequencing in primary central nervous system lymphoma.
Fontanilles M; Marguet F; Bohers É; Viailly PJ; Dubois S; Bertrand P; Camus V; Mareschal S; Ruminy P; Maingonnat C; Lepretre S; Veresezan EL; Derrey S; Tilly H; Picquenot JM; Laquerrière A; Jardin F
Oncotarget; 2017 Jul; 8(29):48157-48168. PubMed ID: 28636991
[TBL] [Abstract][Full Text] [Related]
23. High frequency and clinical prognostic value of MYD88 L265P mutation in primary cutaneous diffuse large B-cell lymphoma, leg-type.
Pham-Ledard A; Beylot-Barry M; Barbe C; Leduc M; Petrella T; Vergier B; Martinez F; Cappellen D; Merlio JP; Grange F
JAMA Dermatol; 2014 Nov; 150(11):1173-9. PubMed ID: 25055137
[TBL] [Abstract][Full Text] [Related]
24.
Narasimhan S; Joshi M; Parameswaran S; Rishi P; Khetan V; Ganesan S; Biswas J; Sundaram N; Sreenivasan J; Verma S; Krishnamurthy V; Subramanian K
Indian J Ophthalmol; 2020 Oct; 68(10):2160-2165. PubMed ID: 32971631
[TBL] [Abstract][Full Text] [Related]
25. Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases.
Dubois S; Viailly PJ; Bohers E; Bertrand P; Ruminy P; Marchand V; Maingonnat C; Mareschal S; Picquenot JM; Penther D; Jais JP; Tesson B; Peyrouze P; Figeac M; Desmots F; Fest T; Haioun C; Lamy T; Copie-Bergman C; Fabiani B; Delarue R; Peyrade F; André M; Ketterer N; Leroy K; Salles G; Molina TJ; Tilly H; Jardin F
Clin Cancer Res; 2017 May; 23(9):2232-2244. PubMed ID: 27923841
[No Abstract] [Full Text] [Related]
26. III. Current concepts in primary central nervous lymphoma.
Illerhaus G
Hematol Oncol; 2015 Jun; 33 Suppl 1():25-8. PubMed ID: 26062049
[No Abstract] [Full Text] [Related]
27. Development of high-resolution melting analysis for the detection of the MYD88 L265P mutation.
Wang CZ; Lin J; Qian J; Shao R; Xue D; Qian W; Xiao GF; Deng ZQ; Yang J; Li Y; Chen XX
Clin Biochem; 2013 Mar; 46(4-5):385-7. PubMed ID: 23178471
[TBL] [Abstract][Full Text] [Related]
28. MYD88 (L265P) Mutation in Malignant Lymphoma Using Formalin-Fixed Paraffin-Embedded Section.
Ogura G; Kikuti YY; Kikuchi T; Carreras J; Sato T; Nakamura N
J Clin Exp Hematop; 2013; 53(2):175-7. PubMed ID: 23995116
[No Abstract] [Full Text] [Related]
29. Programmed Cell Death Ligand 1 Expression in Primary Central Nervous System Lymphomas: A Clinicopathological Study.
Hayano A; Komohara Y; Takashima Y; Takeya H; Homma J; Fukai J; Iwadate Y; Kajiwara K; Ishizawa S; Hondoh H; Yamanaka R
Anticancer Res; 2017 Oct; 37(10):5655-5666. PubMed ID: 28982883
[TBL] [Abstract][Full Text] [Related]
30. The importance of Myd88 L265P mutation, clinical and immunohistochemical prognostic factors for the survival of patients with diffuse large B-cell non-Hodgkin lymphoma treated by immunochemotherapy in southeast Serbia.
Tadic L; Marjanovic G; Macukanovic-Golubovic L; Krstic M; Jevtovic-Stoimenov T; Kostov M; Smelcerovic Z; Stojanovic M
J BUON; 2016; 21(5):1259-1267. PubMed ID: 27837631
[TBL] [Abstract][Full Text] [Related]
31. Impact of treatment variability on survival in immuno-competent and immuno-compromised patients with primary central nervous lymphoma.
Karmali R; Nabhan C; Petrich AM; Raizer J; Peace D; Lukas R; Gordon LI; Basu S; Chukkapalli V; Venugopal P
Br J Haematol; 2017 Apr; 177(1):72-79. PubMed ID: 28211579
[TBL] [Abstract][Full Text] [Related]
32. Significance of MYD88 L265P Mutation Status in the Subclassification of Low-Grade B-Cell Lymphoma/Leukemia.
Insuasti-Beltran G; Gale JM; Wilson CS; Foucar K; Czuchlewski DR
Arch Pathol Lab Med; 2015 Aug; 139(8):1035-41. PubMed ID: 26230596
[TBL] [Abstract][Full Text] [Related]
33. Patients with primary breast and primary female genital tract diffuse large B cell lymphoma have a high frequency of MYD88 and CD79B mutations.
Cao XX; Li J; Cai H; Zhang W; Duan MH; Zhou DB
Ann Hematol; 2017 Nov; 96(11):1867-1871. PubMed ID: 28803429
[TBL] [Abstract][Full Text] [Related]
34. Clinical spectrum of vitreoretinal lymphoma and its association with MyD88 L265P mutation.
Carreno E; Clench T; Steeples LR; Salvatore S; Lee RWJ; Dick AD; Pawade J
Acta Ophthalmol; 2019 Feb; 97(1):e138-e139. PubMed ID: 30113125
[No Abstract] [Full Text] [Related]
35. CD79B and MYD88 mutations in diffuse large B-cell lymphoma.
Kim Y; Ju H; Kim DH; Yoo HY; Kim SJ; Kim WS; Ko YH
Hum Pathol; 2014 Mar; 45(3):556-64. PubMed ID: 24444466
[TBL] [Abstract][Full Text] [Related]
36. MYD88 expression and L265P mutation in mature B-cell non-Hodgkin lymphomas.
Caner V; Sen Turk N; Baris IC; Cetin GO; Tepeli E; Hacioglu S; Sari I; Zencir S; Dogu MH; Bagci G; Keskin A
Genet Test Mol Biomarkers; 2015 Jul; 19(7):372-8. PubMed ID: 25978699
[TBL] [Abstract][Full Text] [Related]
37. MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance.
Varettoni M; Zibellini S; Arcaini L; Boveri E; Rattotti S; Pascutto C; Mangiacavalli S; Gotti M; Pochintesta L; Paulli M; Cazzola M
Blood; 2013 Sep; 122(13):2284-5. PubMed ID: 24072850
[No Abstract] [Full Text] [Related]
38. PREVALENCE OF MYD88 L265P MUTATION IN HISTOLOGICALLY PROVEN, DIFFUSE LARGE B-CELL VITREORETINAL LYMPHOMA.
Raja H; Salomão DR; Viswanatha DS; Pulido JS
Retina; 2016 Mar; 36(3):624-8. PubMed ID: 26900675
[TBL] [Abstract][Full Text] [Related]
39. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.
Treon SP; Xu L; Yang G; Zhou Y; Liu X; Cao Y; Sheehy P; Manning RJ; Patterson CJ; Tripsas C; Arcaini L; Pinkus GS; Rodig SJ; Sohani AR; Harris NL; Laramie JM; Skifter DA; Lincoln SE; Hunter ZR
N Engl J Med; 2012 Aug; 367(9):826-33. PubMed ID: 22931316
[TBL] [Abstract][Full Text] [Related]
40. An update on therapy of primary central nervous system lymphoma.
Deangelis LM; Iwamoto FM
Hematology Am Soc Hematol Educ Program; 2006; ():311-6. PubMed ID: 17124077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
